跳至主要内容
临床试验/NCT05247931
NCT05247931Unknown不适用

Why Does Aspirin Fail in Secondary Cerebrovascular Prevention? A Multicenter Prospective Case - Control Study

Fadoi Foundation, Italy16 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2019年11月7日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
100
试验地点
16
主要终点
To evaluate the rate of recovery of platelet COX-1 activity, measured between 12 and 24 hours after low-dose (100 mg) ASA administration by means of three determinations of serum TXB2 levels, at day 8±1, comparing CASE group vs. CONTROL Group.

研究概览

简要总结

Multicenter prospective observational case-control study aimed at characterizing the possible determinants of treatment failure in patients with cerebrovascular disease on secondary prevention with ASA, who are hospitalized in Internal Medicine departments for a recurrent atherothrombotic stroke.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Age ≥18 years
  • •Swallow-test positive
  • •Patients hospitalized for a first event of athero-thrombotic stroke (CONTROL group)
  • •Patients hospitalized for a recurrence of athero-thrombotic stroke on ASA therapy (CASE group)
  • •Informed Consent

排除标准

  • •Transient ischemic attack (TIA)
  • •Chronic treatment with non-steroidal anti-inflammatory drugs (if occasional, not within 4 days prior to hospitalization)
  • •Current treatment with oral or parental anticoagulants at prophylactic or therapeutic doses
  • •Current treatment with other antiplatelet agents
  • •Thrombolysis and thrombectomy
  • •Cardio-embolic stroke CENTRO STUDI FONDAZIONE FADOI Page 10 Studio FADOI.01.2018 Versione n. 2 del 26/09/2019
  • •Carotid stenosis >70%, with indication for revascularization
  • •Current treatment with ASA (only for patients in the CONTROL group)
  • •Acute hepatitis, chronic active hepatitis, liver cirrhosis - or alanine aminotransferase level 3 times or more and/or bilirubin level 2 times or more higher than the upper limit of the normal range
  • •Thrombocytopenia (<150000 platelets/μl)
  • •Renal failure (eGFR <30 ml/min)
  • •Active cancer or disease in complete remission <1 year, except squamous cell carcinoma and basal-cell carcinoma of the skin at initial stage
  • •Severe chronic obstructive pulmonary disease (COPD) (oxygen therapy)
  • •Uncontrolled hypertension (systolic BP >180 mmHg or diastolic BP >100 mmHg despite antihypertensive treatment)
  • •Chronic inflammatory bowel disease
  • •Chronic treatment with corticosteroid drugs (for example Prednisone >5 mg/die or equivalent)
  • •Pregnancy (in case of child-bearing potential inclusion will be possible in case of negative pregnancy test)

结局指标

主要结局

To evaluate the rate of recovery of platelet COX-1 activity, measured between 12 and 24 hours after low-dose (100 mg) ASA administration by means of three determinations of serum TXB2 levels, at day 8±1, comparing CASE group vs. CONTROL Group.

时间窗: day 8±1

To evaluate the rate of recovery of platelet COX-1 activity, measured between 12 and 24 hours after low-dose (100 mg) ASA administration by means of three determinations of serum TXB2 levels, at day 8±1, comparing CASE group vs. CONTROL Group.

次要结局

未报告次要终点

研究者

发起方
Fadoi Foundation, Italy
申办方类型
Other
责任方
Sponsor

研究点 (16)

Loading locations...

相似试验